PND59 Drug Compliance and Persistence in Patients with Parkinson’s Disease Treated in Primary Care in the United Kingdom: A CPRD-Based Study  by Bineau, S. et al.
A628  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
A multi-center retrospective chart-review study of MS patients conducted in United 
Kingdom (UK), France (FR), Germany (DE), Italy (IT), Spain (SP) and US to collect 
de-identified data on diagnosis, clinical status and DM approaches. Health care 
providers (HCPs; 95% neurologists) were screened for duration of practice (> = 3yrs) 
and patient volume (> = 15 MS patients/month) and recruited from a large panel to be 
geographically representative in each country. Medical charts of next 10 consecutive 
MS patients were selected by each physician. Results: A total of 3490 eligible MS 
patient charts were abstracted by 360 HCPs (mean age:47yrs; female: 31%; mean 
practice duration:18yrs; mean # of patients seen per month:63; % working in spe-
cialty MS clinic:45%). Patient mean age: 39yrs; female: 66%; top-5 comorbidities: 
depression (14%), anxiety (10%), hypertension (8%), obesity (7%), migraine/headache 
(6%). Tests used by physicians to diagnose MS varied between the countries (UK/
FR/DE/IT/SP/US: %): History/Neurological exam – 79/88/99/95/97/88, Gadolinium 
MRI – 56/93/66/93/96/89, T1 MRI – 49/89/80/84/93/74, T2 MRI – 65/89/66/91/94/82, 
CSF analysis – 51/82/71/3/90/56, Evoked potentials – 34/48/65/77/80/29. Patients 
with moderate/severe disease and currently on disease modifying treatments 
(DMTs) varied (UK/FR/DE/IT/SP/US: %): 50/45/37/58/50/47 & 52/71/75/77/73/78; cor-
respondingly, tests used by physicians to assess MS disease progression/activity 
also varied between the countries (UK/FR/DE/IT/SP/US: %): EDSS–63/83/84/91/92/40, 
Neurological exam–81/91/88/89/84/86, Gadolinium MRI–33/69/36/90/68/70, T1 MRI–
21/53/53/76/54/54, T2 MRI–29/62/41/89/63/65, Ambulation index–9/13/9/24/16/19, 
Brain atrophy–4/14/6/23/15/18, Nine hole peg test–6/3/10/5/3/1 and PASAT–
1/0/12/5/4/1. ConClusions: UK physicians appear to under-utilize the tests to 
diagnose/manage MS patients, whereas physicians in Spain often used them more 
frequently. Observed trends were not correlated to the patient disease severity 
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objeCtives: Differences in compliance and persistence between Parkinson’s dis-
ease (PD) drugs were found in a previous US claim database analysis. The objective 
was to apply the same methodology in another setting using the Clinical Practice 
Research Datalink (CPRD) in the UK. Methods: A retrospective analysis of patients 
starting a new PD drug (rasagiline, selegiline, pramipexole, ropinirole, entacapone, 
tolcapone, levodopa) between January 2009 and January 2012 was conducted using 
CPRD. Patients were categorized as naive to PD therapy (NT) or having prior PD 
therapy (PT), depending on the prescription of other PD drugs within a 12-month 
look-back period. The observation period was 12 months. Compliance was measured 
using the medication possession ratio (MPR) and non-compliance was defined as 
an MPR≤ 80%. Persistence was measured as the duration (days) of uninterrupted 
therapy without gap higher than 45 days. Results: Of the 4,784 patients included 
in the compliance analysis, 3,675 patients (76.8%) had compliance rates > 80%. Mean 
MPRs were generally comparable across PD products (range:84%-90%, all pairwise 
p= NS). Percentage of patients with MPR> 80% was significantly greater with rasagil-
ine (85.6%, all p< 0.05 except vs. ropinirole p= NS). Of the 5,266 patients included in 
the persistence analysis, the highest mean number of persistent days of treatment 
was reported for rasagiline (284 days; all p< 0.05 vs others, except vs. ropinirole 
p= 0.14 and levodopa p= 0.06). Patient persistence at 12 months was significantly 
greater with rasagiline compared with others in NT patients (66.5%, all p< 0.05) 
scenarios even though that the additional clinical benefit profile was uncertain and 
pricing not optimal. When developing potential budget estimates based on sample 
size and complexity of a clinical trial for motor fluctuations or dyskinesias as pri-
mary endpoint a significant clinical benefit was highly likely and premium pricing 
possible. However, a positive investment decision was uncertain due to the high 
development cost. ConClusions: Even though there are incentives to add patient 
relevant endpoints in the development programmes the return on investment could 
potentially not be high enough for a positive investment decision. Target profiling 
including market access and pricing outcomes could optimize investment decisions.
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ReCeIvINg DIseAse moDIfyINg TReATmeNTs IN euRoPe AND THe uNITeD 
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objeCtives: To assess clinical characteristics of MS patients not on any DMTs in key 
countries in European Union (EU) and the U.S. Methods: A multi-country multi-
center medical chart-review study of MS patients was conducted in 4Q2012 among 
Health care providers (HCPs; > 85% neurologists) in hospitals and private practices 
to collect de-identified data. HCPs from UK, Germany, France, Italy and Spain (5EU) 
and the US were screened for duration of practice (> = 3yrs) and patient volume 
(> = 15 MS patients/month) and recruited from a large panel to be geographically 
representative in each country. Medical charts of next 10 consecutive MS patients 
were completed by each physician. HCPs abstracted patient diagnosis, treatment 
patterns and patient symptomatology/disease status. MS patients not on any 
DMTs were analyzed. Results: A total of 967 eligible MS patients were included 
in the analysis (5EU:749; US:218). Mean age (yrs) – 5EU:39.0yrs, US:42.2yrs; Female – 
5EU:69%; US:67%. Key reasons for not receiving DMTs were (5EU/US): mild/early-MS 
(35%/36%), patient refusal (26%/44%), progressive/severe/advanced-MS (20%/17%), 
lack of efficacy of current treatment options (10%/14%), side-effects/tolerance/co-
morbidities (6%/12%), waiting for DMTs to become available (5%/12%) and funding/
authorization/guidelines (4%/7%). Among patients who refused DMTs, more than 
half were not convinced of therapy benefits. Distribution of MS type was (5EU/US): 
Clinically Isolated Syndrome (CIS)-26%/25%, Relapse Remitting MS (RRMS)-44%/49% 
and Secondary Progressive MS (SPMS)-30%/26%. Patients with moderate/severe dis-
ease and those with active/highly active disease (both, per physician judgment) 
were (5EU/US): CIS:10%/11%, RRMS:25%/40%, SPMS:95%/86%, and CIS:31%/44%, 
RRMS:39%/37%, SPMS:36%/32% respectively. Mean Expanded Disability Status Scale 
score were (5EU/US): CIS:0.8/0.7, RRMS:1.8/2.2, SPMS:6.5/5.6); % patients currently 
suffering a relapse were (5EU/US): CIS:20%/29%, RRMS:21%/15%, SPMS:6%/16%; 
% patients with > = 1 relapses in last 12months were (5EU/US): CIS:69%/69%, 
RRMS:52%/58%, SPMS:18%/32%. ConClusions: Among MS patients not on any 
DMTs, disease burden seems substantial. Further research is warranted to scrutinize 
the observed patient management practices to alleviate patient burden.
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objeCtives: To assess disease burden of SPMS patients treated with DMTs in 
EU and the U.S. Methods: A multi-country chart-review study of SPMS patients 
was conducted among neurologists in hospitals/private practices to collect de-
identified data. Neurologists from UK/Germany/France/Italy/Spain (5EU) and 
US were screened for practice-duration (> = 3yrs) and patient-volume (> = 15MS 
patients/month) and recruited from a large panel to be geographically representa-
tive in each country. Charts of next 2 consecutive SPMS patients were selected 
by each neurologist. Neurologists abstracted patient diagnosis, treatment pat-
terns and patient symptomatology/disease status. SPMS patients on DMTs were 
analyzed. Results: In 4Q2012, 360 Neurologists (5EU:259; US:101) abstracted 699 
eligible SPMS patient charts (5EU:497; US:202); 420 (5EU:274; US:146) patients were 
managed with DMTs. Mean age – 5EU:46.5yrs, US:49.2yrs; Female – 5EU:58%; US:66%. 
Mean time-to-1st DMT initiation (5EU/US; months) from diagnosis was 21/27; cur-
rent DMT patterns (5EU/US) were: 1st line (25%/34%), 2nd line (39%/38%) & 3rd+ 
line (36%/28%). Interferon beta-1b (5EU) and glatiramer acetate (US) were predomi-
nantly observed in 1st/2nd line; fingolimod and natalizumab use was observed 
in 2nd-line but they dominated later lines. Mean time-to-1stDMT initiation (5EU/
US: months) from diagnosis (1st:45/35, 2nd:13/30, 3rd+:12/10) and mean treatment 
time (5EU/US: months) on current 1st (85/91), 2nd (38/35; prior 1st line: 57/48) and 
3rd+ line (19/24; prior 2nd line: 35/46) differed. Patients with severe disease and 
those with active/highly active disease (both, per physician judgment) were (5EU/
US): 1st:15%/20%, 2nd:20%/18%, 3rd+:35%/37% and 1st:45%/61%, 2nd:63%/73%, 
3rd+:57%/68% respectively; mean Expanded Disability Status Scale scores also dif-
fered (5EU/US): 1st:5.1/5.0, 2nd:5.6/5.5, 3rd+:5.8/6.1. ConClusions: Among SPMS 
patients currently managed with DMTs, the disease burden increased as the line 
of treatment increased, both in 5EU and the US. Patients in 2nd/3rd+line of treat-
ments had progressed through earlier line(s) of treatment quickly. Further research 
is warranted to scrutinize the effectiveness of therapeutic options and sequencing 
strategies to alleviate patient burden.
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PATTeRNs of use of TesTs To DIAgNose AND Assess DIseAse PRogRessIoN 
IN mulTIPle sCleRosIs (ms): A mulTICouNTRy ComPARIsoN
Narayanan S.1, Khan H.2, Gabriele S.2, White J.2
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objeCtives: To assess the patterns of use of tests to diagnose and assess disease 
progression/activity in MS in the European Union and United States (US). Methods: 
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A629
ment was associated with 38% fewer unplanned admissions (981 vs. 604, X1
2 = 
89.2, p< 0.001) and 58% fewer unplanned bed nights (8,817 vs. 3,681, X12 = 2109.8, 
p< 0.001) in the year following treatment initiation compared with the year before. 
A 14% reduction in all outpatient appointments was also observed, due principally 
to a 25% reduction in neurological outpatient appointments (from 7,826 to 5,901, 
X1
2 = 269.7, p< 0.001). Evidence from this study indicates that duration of treat-
ment is a significant factor in this response; patients receiving between 12 and 
14 doses (n= 1,122) experienced 70% reduction in unplanned admissions and 90% 
reduction in unplanned bed nights. ConClusions: Our data support the notion 
that natalizumab treatment significantly reduces unplanned hospital treatment 
and outpatient attendance.
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Tomita N., Kanatani Y.
National Institute of Public Health, Wako, Japan
objeCtives: Parkinson’s disease has the second largest number of patients among 
56 designated diseases/syndrome of the Specified Disease Treatment Research 
Programme for rare and intractable disease programme. The purpose of this study 
were to investigate prescribing patterns of Parkinson’s disease and its pharmaceuti-
cal expenditures. Methods: We analysed the Social Health Insurance (SHI) claims 
data processed from February to April 2011 provided by the Planning, Review and 
Research Institute for Social Insurance and Medical Program. Results: During the 
three months, 52,851 patients in Social Health Insurance programme received medi-
cal treatments that cost 9,391,451,520 JPY. Average costs for inpatient care without 
meal expense and for outpatient care were 263,782 JPY and 33,209 JPY respectively. 
Except the cases that fell into Diagnosis Procedure Combination (DPC), 37% of the 
total cost, 3,515,091,420 JPY was for pharmaceutical expenditure including dispens-
ing fee. Only 7,437,873 (23.5%) of 31,699,153 dispensed drugs were generics on a 
volume basis. If all the pharmaceutical that have generics had been substituted, 
estimated 899,586,280 JPY would have been saved in the study period by simple 
arithmetic. Generic usage is fewer in the elderly than in the younger generation in 
all therapeutic categories. ConClusions: Percentage of pharmaceutical expend-
iture in total health expenditure for Parkinson’s disease is high. Our study find 
that generic substitution rate is low in general and even lower in the elderly. This 
might be partly related to the medical expense subsidy under the Specified Disease 
Treatment Research Programme, which exempts eligible patients from co-payment 
according to their income. There seems to be a room for prescribing pattern change 
for cost optimization and further study is expected.
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objeCtives: To describe and to estimate costs of formal and informal home care 
and quality of life related to multiple sclerosis. Methods: A random sample of 
1500 members of the Swedish organization for patients with neurological diseases 
(NHR), specifically MS, were mailed a questionnaire between February-March 2012. 
Collected data included number of hours per month of home care received, type 
of help, productivity losses, quality of life (EQ-5D) and disease characteristics. The 
recall period was one month. Using published Swedish unit cost data, the costs 
for home care were estimated in 2012 euros. A semi-logarithmic linear regres-
sion evaluated other factors that may influence the likelihood of getting home 
care. Results: Of 839 respondents, 65.5% had progressive MS, 24.5% had RRMS 
and 10% had no information. Formal care was given to 27% of respondents at 
an average of 238.7 hrs/month at a mean cost of € 2873 per person with MS per 
month. Informal care was received by 49% of respondents at an average of 47.3 
hrs/month at a mean cost of € 389 per person with MS per month. Based on disease 
severity, the mean total home care costs/patient/month were: mild (EDSS 0-3) = 
€ 63, moderate (EDSS 4-6) = € 461 and severe (EDSS > 6.5) = € 8446. Total home care 
costs were three-fold higher in persons with moderate MS and seven-fold higher 
in persons with severe MS versus mild MS. Total home care costs of patients 
cohabiting with another person were nearly 70% higher compared to people liv-
ing alone. The reported average utility was 0.513 (sd 0.307). Utilities across dis-
ease severity: mild MS= 0.709 (sd 0.233), moderate MS= 0.562 (sd 0.232) and severe 
MS= 0.284(sd 0.283). ConClusions: Total home care costs, of which formal care 
costs accounted for a large proportion, increased with increasing disease severity. 
Informal caregiving contributes significantly to MS home care and is an important 
complement to formal home care in Sweden.
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objeCtives: To explore the demographics, comorbidities and medication 
exposure of Down Syndrome (DS) patients in Utah compared to a national 
cohort. Methods: National and local data on adult patients with DS were 
extracted from the General Electric Healthcare National Clinical Data Services 
Warehouse and the University of Utah Healthcare System Enterprise Data, respec-
tively. The ICD-9 code for Down Syndrome (758.0) was used to identify patients, 
alive through 2012, and their associated comorbidities and prescribed medications. 
We used descriptive statistics, t-test, test of proportion and Fisher’s exact test to 
examine relationships between demographics, comorbidities and pharmacothera-
pies and compared results between local and national cohorts. Results: Data was 
extracted on 513 patients in Utah and 11,736 nationally, 98% and 64% of patients 
are adults in cohorts, respectively. Through 2012, adult DS patients in Utah were 
younger (37 vs. 39, p< 0.005), more likely to be female (54.08% vs. 50.47%, p< 0.05) 
and with levodopa in PT patients (72.7%, all p< 0.05). ConClusions: A high and 
comparable level of compliance was observed across PD drugs. Persistence was 
significantly higher than other drugs with rasagiline in treatment-naïve patients 
and with levodopa in previously treated patients.
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objeCtives: To analyze determinants of recent evolution of DMT consumption for 
MS in Spain. Methods: Available DMT market data comprised monthly figures 
for the period 2004-2012. Monthly and annual evolution of consumption, treated 
patients and annual cost of treatment were calculated for each DMT. This analy-
sis was replicated for first-line (intramuscular and subcutaneous interferon (IFN) 
β -1a, subcutaneous IFN β -1b, and glatiramer acetate) and second-line therapies 
(natalizumab and fingolimod). Evolution of these variables was analyzed for both 
the whole period 2004-2012 and since 2007 (when second-line therapies become 
available in Spain). Results: DMT expenditure in Spain increased by 147% in 2004-
2012 (from € 115.5M to € 284.9M, 11.95% annually). This evolution can be decomposed 
into: the growth in the figure treated patients (126%; 10.70% annually) and the 
increase in the average annual cost per patient (9%, from € 11,739 to € 12,839; 1.13% 
annually). For 2007-2012 subperiod, DMT spending increased by 73% (11.57% annu-
ally) is attributable to 59% more treated patients (9.73% annually) and an increase 
of 9% (1.68%) in annual cost per patient. Cost per patient in second-line is 70% 
higher (average 2007-2012) than average cost per treated patient (€ 21,074 vs. € 
12,372) and 82% higher than annual cost of first-line therapy (€ 21,074 vs. € 11,549). 
Between 2007 and 2012, second-line therapies accounted 32% of new treatments 
and 48% of incremental cost per patient. By omitting year 2007 from analysis (68 
second-line treatments and € 1.44M associated consumption), second-line therapies 
account for 38% of new treatments and 55% of incremental cost per patient. By 2012 
second-line therapies already represent 50% of new treatments and 67% of DMT 
cost increase. ConClusions: The increase of patients treated with DMT in Spain 
(10.70% annually in 2004-2012), more costly new therapies incorporation and its 
growing consumption are crucial factors in handling hospital pharmacy budgets 
for prevalent diseases such as MS.
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objeCtives: To investigate the characteristics and extent of health care utiliza-
tion among patients with Parkinson’s disease (PD) with and without non-motor 
symptoms (NMS). Methods: Data were obtained from a US administrative claims 
database (SDI/IMS). Index date was 1 June 2010, and study duration was 12 months. 
Patients were required to have at least two PD diagnoses before the index date. They 
were subsequently matched 1:1 to control patients (no PD diagnoses) based on 
propensity scores derived from age and pre-index Charlson comorbidity index for 
each gender. Results: In total, 127,630 patients with PD were matched to controls. 
Patients with PD had higher annual mean numbers of primary care (16.4 vs 12.3; 
p ≤ 0.0001) and neurologist visits (6.7 vs 0.4; p ≤ 0.0001) compared with matched 
controls. In the PD group, 48,823 patients (38.3%) had a diagnosis for at least one 
NMS, of whom 15,242 (31.2 %) were also treated for at least one NMS. Most fre-
quently reported NMS were pain (27.2%), mood disturbance (depression, anxiety or 
nervousness; 12.7%) and sleep disorder (7.4%). Patients with pain, mood and sleep 
disorders (n= 1,159), had higher total annual primary care and neurologist visits 
than patients with no NMS (50.7 vs. 17.2). Patients who received treatment for pain, 
mood and sleep disorders (n= 118), had a higher total number of annual primary care 
and neurologist visits (66.6) compared with patients treated only for mood (26.0; 
n= 3,233) only for pain (35.6; n= 9,432), or only for sleep (30.6; n= 676). ConClusions: 
Results of the study demonstrate that treatment of NMS increases health care uti-
lization – patients with PD suffering from NMS had a substantially greater number 
of health care visits than those with no NMS. Results also indicate that there are 
substantial levels of undertreatment of NMS among patients with PD, with less 
than a third being treated.
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NATAlIzumAB TReATmeNT Is AssoCIATeD WITH ReDuCeD NeuRology 
ouTPATIeNT APPoINTmeNTs, uNPlANNeD HosPITAl ADmIssIoNs AND 
leNgTH of sTAy
Beadman A, Hanna J
Biogen Idec Limited, Maidenhead, UK
objeCtives: Global wellbeing of patients is an important outcome in research and 
clinical practice. Multiple Sclerosis (MS) is a degenerative, neurological condition, 
characterised by progressive disability, affecting approximately 110 per 100,000 
people in England and Wales. Natalizumab is a humanised monoclonal antibody, 
licensed for use in highly active relapsing-remitting MS and administered as an 
IV infusion every 28 days. The purpose of this study was to explore the impact of 
natalizumab on both patients and use of health service resource in clinical practice 
in England. Methods: Health Episode Statistics (HES) data were used to perform 
a retrospective cohort study. A structured coding search elucidated a compre-
hensive list of natalizumab users by hospital trust. Analysis of health service 
usage, including outpatient appointments and admissions, was undertaken. 
Comparison of use during the year before and after treatment initiation was con-
ducted. Results: A total of 2,196 patients with at least 1 year of available HES 
data after treatment initiation were identified. In this cohort, natalizumab treat-
